TheraRadar
Clinical-Stage Companies / Crucell Holland

Crucell Holland

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 9/21/2015

33
Total Trials
10
Phase 3
6
Phase 2
0
Recruiting
234
Score

Pipeline by Phase

Phase 3
10
Phase 2
6
Phase 1
12

Therapeutic Focus

Influenza Healthy Hepatitis B Diphtheria Pertussis

Clinical Trials (33)

NCT02543268 Phase 3 COMPLETED

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Started: 9/21/2015

NCT01917357 Phase 3 COMPLETED

A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject

Started: 9/1/2013

NCT01349283 Phase 3 COMPLETED

Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns

Started: 5/1/2011

NCT01229397 Phase 3 COMPLETED

Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V

Started: 10/1/2010

NCT01310400 Phase 3 COMPLETED

Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children

Started: 10/1/2009

NCT01631110 Phase 3 COMPLETED

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains

Started: 7/1/2012

NCT01362517 Phase 3 COMPLETED

Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B

Started: 4/1/2010

NCT01229371 Phase 3 COMPLETED

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers

Started: 10/1/2010

NCT01412281 Phase 3 COMPLETED

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers

Started: 10/1/2011

NCT01893177 Phase 3 COMPLETED

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)

Started: 7/1/2013

NCT01938352 Phase 2 COMPLETED

Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge

Started: 10/2/2013

NCT01992276 Phase 2 WITHDRAWN

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

Started: 12/1/2013

NCT01228383 Phase 2 COMPLETED

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Started: 12/1/2011

NCT00708084 Phase 2 COMPLETED

Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents

Started: 5/1/2008

NCT00656097 Phase 2 COMPLETED

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

Started: 3/1/2008

NCT02218125 Phase 1 COMPLETED

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

Started: 9/23/2014

NCT02440035 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

Started: 4/21/2015

NCT02313077 Phase 1 COMPLETED

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Started: 12/17/2014

NCT02376426 Phase 1 COMPLETED

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Started: 3/1/2015

NCT02376400 Phase 1 COMPLETED

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Started: 4/1/2015

NCT02561871 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

Started: 9/1/2015

NCT02304185 Phase 1 COMPLETED

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

Started: 12/1/2014

NCT02148328 Phase 1 COMPLETED

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

Started: 5/1/2014

NCT01617239 Phase 1 COMPLETED

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

Started: 6/1/2012

NCT01406418 Phase 1 COMPLETED

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Started: 2/1/2013

NCT01756950 Phase 1 COMPLETED

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Started: 1/1/2013

NCT01397227 Phase 1 COMPLETED

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

Started: 6/1/2011

NCT01349829 Phase 4 COMPLETED

A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children

Started: 3/1/2010

NCT01306305 Phase 4 COMPLETED

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere

Started: 6/1/2010

NCT01357720 Phase 4 COMPLETED

Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination

Started: 5/1/2011

NCT01306253 Phase 4 COMPLETED

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere

Started: 6/1/2009

NCT01303510 Phase 4 COMPLETED

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere

Started: 7/1/2008

NCT01457027 Phase 4 COMPLETED

A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season

Started: 10/1/2011

Drug Candidates

Ad26.ZEBOV-Batch #1 Ad26.ZEBOV-Batch #2 Ad26.ZEBOV-Batch #3 MVA-BN-Filo Placebo CR8020 MVA Mosaic Ad35.RSV.FA2 Ad26.RSV.FA2 MVA-BN-filo
Activity Status: Inactive
Last Trial Started: 9/21/2015
Last Trial Ended: 9/1/2016
Trials (12 months): 0
Completed Trials: 32
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.